ROBYN BARLOW: Open Payments
NPI 1558131078 · COLUMBIA, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,143 in 155 payments from 19 companies in 2025. Trend: 2023 $26 · 2024 $2,845 · 2025 $3,143
Food & beverage: $3,059Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 52 | $1,083 |
| Janssen Biotech, Inc. | 18 | $426 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $313 |
| Regeneron Healthcare Solutions, Inc. | 8 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $180 |
| Celltrion USA Inc. | 8 | $175 |
| Lilly USA, LLC | 6 | $173 |
| Madrigal Pharmaceuticals | 9 | $149 |
| Gilead Sciences, Inc. | 4 | $71 |
| Phathom Pharmaceuticals, Inc. | 5 | $57 |
Products named: RINVOQ, TREMFYA, XIFAXAN, SKYRIZI, DUPIXENT, LINZESS, VEGZELMA, OMVOH.
Industry payments across MO — which companies pay providers there.
